Applied Spectral Imaging Ltd.
7
0
0
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
14.3%
1 terminated/withdrawn out of 7 trials
85.7%
-0.8% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (7)
Identification and Semi-Quantification of Ki-67 Protein Expression Status
Role: lead
Identification and Semi -Quantification of ER/PR Proteins Expression
Role: lead
Semi-Quantification of Her2/Neu Protein Expression in Formalin Fixed, Paraffin-Embedded Normal and Neoplastic Tissue
Role: lead
Immunohistochemical (IHC) Scoring for Receptors Expression in Breast Tissues
Role: lead
Detection of Chromosomal Aberrations in Non-small Cell Lung Cancer (NSCLC) Using Fluorescent in Situ Hybridization (FISH) (ALK Test)
Role: lead
Detection of Chromosomal Aberrations in Urine Samples Using Fluorescent in Situ Hybridization (FISH) (UroVysion Test)
Role: lead
Detection of Amplification of Her2 Fluorescent in Situ Hybridization (FISH) in Breast Tissue Sections
Role: lead
All 7 trials loaded